This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Current standard of care treatment options available for ATTR-CM are aimed at symptom management, supportive care including pain management, nutritional and mobility support and mitigation of the effects of the disease on other organs.1
In February 2020, marketing authorisation in the United Kingdom was granted for Vyndaqel▼ (tafamidis), a transthyretin stabiliser, available as a once-daily 61 mg oral capsule2, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Whilst there is a licence for Vyndaqel for ATTR-CM in the UK, there is not currently funded NHS access.
Additional treatment options are currently under investigation. Emerging treatment strategies are aimed at reducing the formation of the amyloid fibrils by targeting different stages of their development.3
Note: Some of these are investigational approaches, and no conclusions can be made about safety and efficacy.
See other educational resources available
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. October 2020
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021